CA2938501C - Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires - Google Patents

Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires Download PDF

Info

Publication number
CA2938501C
CA2938501C CA2938501A CA2938501A CA2938501C CA 2938501 C CA2938501 C CA 2938501C CA 2938501 A CA2938501 A CA 2938501A CA 2938501 A CA2938501 A CA 2938501A CA 2938501 C CA2938501 C CA 2938501C
Authority
CA
Canada
Prior art keywords
radical
conjugate
pro
function
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2938501A
Other languages
English (en)
French (fr)
Other versions
CA2938501A1 (fr
Inventor
Sebastien Papot
Isabelle Opalinski
Brigitte Renoux
Thibaut LEGIGAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
University of Poitiers
Original Assignee
Centre National de la Recherche Scientifique
University of Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, University of Poitiers filed Critical Centre National de la Recherche Scientifique
Publication of CA2938501A1 publication Critical patent/CA2938501A1/fr
Application granted granted Critical
Publication of CA2938501C publication Critical patent/CA2938501C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2938501A 2014-02-07 2015-02-06 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires Active CA2938501C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1450956 2014-02-07
FR1450956A FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
PCT/IB2015/050914 WO2015118497A1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Publications (2)

Publication Number Publication Date
CA2938501A1 CA2938501A1 (fr) 2015-08-13
CA2938501C true CA2938501C (fr) 2022-04-05

Family

ID=50829100

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2938501A Active CA2938501C (fr) 2014-02-07 2015-02-06 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Country Status (12)

Country Link
US (1) US10293021B2 (enExample)
EP (2) EP3766510B1 (enExample)
JP (1) JP6721512B2 (enExample)
CN (2) CN106573071A (enExample)
CA (1) CA2938501C (enExample)
DK (2) DK3139963T3 (enExample)
ES (2) ES2843798T3 (enExample)
FI (1) FI3766510T3 (enExample)
FR (1) FR3017298B1 (enExample)
LT (1) LT3766510T (enExample)
PT (1) PT3766510T (enExample)
WO (1) WO2015118497A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11384104B2 (en) 2015-06-19 2022-07-12 Centurion Biopharma Corporation Delivery systems for controlled drug release
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
ES2948846T3 (es) 2016-03-29 2023-09-20 Toray Industries Derivado peptídico y uso del mismo
US11666657B2 (en) 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
BR112020009836A2 (pt) * 2017-11-30 2020-10-13 Centurion Biopharma Corporation pró-drogas de ligação a albumina de derivados de auristatina e
HRP20241363T1 (hr) * 2018-04-03 2024-12-20 Syndivia Konjugat citotoksičnog lijeka i oblik predlijeka navedenog konjugata
CA3139378A1 (en) 2019-05-06 2020-11-12 Seekyo New therapeutic vectors and prodrugs for treating cancers
FR3126982B1 (fr) * 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CN116077674B (zh) * 2022-12-26 2025-03-25 北京大学 生物分子-聚氮氧化物偶联物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
HUE035853T2 (en) * 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
FR2960153B1 (fr) * 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant

Also Published As

Publication number Publication date
PT3766510T (pt) 2026-07-17
DK3139963T3 (da) 2020-10-26
EP3139963A1 (fr) 2017-03-15
EP3139963B1 (fr) 2020-10-07
FR3017298B1 (fr) 2016-03-04
FI3766510T3 (fi) 2026-07-08
LT3766510T (lt) 2026-07-27
EP3766510A1 (fr) 2021-01-20
ES2843798T3 (es) 2021-07-20
US10293021B2 (en) 2019-05-21
JP2017506628A (ja) 2017-03-09
CN114917358A (zh) 2022-08-19
CN106573071A (zh) 2017-04-19
US20170095525A1 (en) 2017-04-06
DK3766510T3 (da) 2026-06-29
JP6721512B2 (ja) 2020-07-15
CA2938501A1 (fr) 2015-08-13
FR3017298A1 (fr) 2015-08-14
EP3766510B1 (fr) 2026-05-13
ES3074632T3 (es) 2026-07-22
WO2015118497A1 (fr) 2015-08-13

Similar Documents

Publication Publication Date Title
EP3139963B1 (fr) Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires
Ferriz et al. Prodrug design of phenolic drugs
EP2571528A1 (fr) Nouveaux bras autoréactifs et prodrogues les comprenant
EP2499150B1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
JP2019023219A (ja) Ｍｅｔａｐ２阻害剤及び肥満症の治療方法
EP1349578B1 (fr) Association medicamenteuse d'une biguanine (metformine) et d'arginine
CA3097622A1 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
US20220017538A1 (en) Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
JP2021530445A (ja) 複素環およびアミノ基によって置換されたピリジン誘導体
EP2662382A1 (fr) Dérivés de stérol, leur procédé de préparation, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement du glioblastome multiple
TW202428569A (zh) 妥布賴森(tubulysins)及其中間產物之製備方法
WO2022229576A1 (fr) Derives hydroxybisphosphoniques de meloxicam pour traitement des maladies inflammatoires osteoarticulaires
EP4401787B1 (fr) Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CA2435483A1 (fr) Utilisation en tant que medicament d'un compose restituant in vivo des principes actifs
HK1236815A1 (en) Conjugates and prodrugs for treating of cancer and inflammatory diseases
WO2025261479A1 (zh) 以丁二酰基为连接链的偶联物及其制备方法和用途
HK40100603A (en) Lymph directing prodrugs
HK40100604A (en) Lymph directing prodrugs
EP3237015A1 (fr) Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine
FR2967675A1 (fr) Derives fluorescents de cyanines polyamines en tant que sonde de diagnostic
JP2022531612A (ja) がん治療のための新規治療用ベクター及びプロドラッグ
CA2780627A1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200106

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250121